Spanish drug development company working on new molecules for conditions with no effective therapy, including spinal cord injury, post-COVID fatigue and certain symptoms of Parkinson's disease, running its programmes jointly with Pharmaceutical Innovation Services.
No comments available.
Leave your rating & comment